Nov 11 (Reuters) - Neuphoria Therapeutics Inc NEUP.O:
NEUPHORIA ANNOUNCES INITIATION OF STRATEGIC REVIEW TO MAXIMIZE STOCKHOLDER VALUE
NEUPHORIA THERAPEUTICS: CONFIRMS RECEIPT OF UNSOLICITED INDICATION OF INTEREST AND DIRECTOR NOMINATIONS FROM LYNX1 MASTER FUND LP
NEUPHORIA THERAPEUTICS INC - ON NOV 10, LYNX1 MASTER FUND OFFERS $5.20 PER SHARE IN CASH FOR NEUPHORIA
Source text: ID:nGNX7PmsfF
Further company coverage: NEUP.O
((reuters.briefs@thomsonreuters.com;))